Amyotrophic lateral sclerosis & frontotemporal degeneration · 2026
ALS untangled #83: clenbuterol.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Burgess Adam, Allen Olivia, Barkhaus Paul, Barnes Benjamin, Benatar Michael, Bertorini Tulio, Bowser Robert, Mascias Cadavid Javier, Carter Gregory T, Cudkowicz Merit, Denson Keelie, Dyckman Kara, Elsharif Basil, Feldman Eva, Foucher Juliette, Fullum Timothy, Glass Jonathan, Helmold Benjamin, Jackson Carlayne, Jhooty Sartaj, Leday Ariah, Mallon Elise, Mcdermott Christopher, Olby Natasha, Ostrow Lyle, Pattee Gary, Pioro Erik, Ratner Dylan, Sang Hemangi, Tito Elia, Vieira Fernando, Wicks Paul, Bedlack Richard, Gelevski Dario
Аннотация
ALS Untangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review clenbuterol, a β-2 adrenergic agonist, as a potential treatment for amyotrophic lateral sclerosis (ALS). Clenbuterol has biological effects that could be relevant to the pathophysiology of ALS such as inducing muscle hypertrophy, improving mitochondrial function, and reducing neuroinflammation. Two studies in mouse models of motor neuron disease and two open label trials suggest possible benefits. However these have methodological flaws which limit interpretation. Clenbuterol can have an array of side effects, some severe. Drop-outs due to side effects were very common in one of the ALS trials and in a separate expanded access program. Based on this information, we cannot currently endorse clenbuterol as an ALS treatment, but we do hope to see further studies of it, or another long acting β-2 adrenergic agonist in people with ALS.